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AbstrAct:
BACKGROUND: Preclinical data indicate EGFR signals through both kinase-
dependent and independent pathways and that combining a small-molecule EGFR 
inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models. 
METHODS: We conducted a dose-escalation, phase I study combining erlotinib, 
cetuximab, and bevacizumab. The subset of patients with non-small cell lung cancer 
(NSCLC) was analyzed for safety and response.
RESULTS: Thirty-four patients with NSCLC (median four prior therapies) received 
treatment on a range of dose levels. The most common treatment-related grade ≥2 
adverse events were rash (n=14, 41%), hypomagnesemia (n=9, 27%), and fatigue 
(n=5, 15%). Seven patients (21%) achieved stable disease (SD) ≥6 months, two 
achieved a partial response (PR) (6%), and two achieved an unconfirmed partial 
response (uPR) (6%) (total=32%). We observed SD≥6 months/PR/uPR in patients 
who had received prior erlotinib and/or bevacizumab, those with brain metastases, 
smokers, and patients treated at lower dose levels. Five of 16 patients (31%) with 
wild-type EGFR experienced SD≥6 months or uPR. Correlation between grade of rash 
and rate of SD≥6 months/PR was observed (p<0.01). 
CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was 
well-tolerated and demonstrated antitumor activity in heavily pretreated patients 
with NSCLC. 
INtrODUctION
The epidermal growth factor receptor (EGFR) is a 
receptor tyrosine kinase that plays an important role in 
tumorigenesis [1], and signals via downstream effectors 
[2]. EGFR mutations are seen in ~13% of patients with 
non-small cell lung cancer (NSCLC) in the United States 
[3], with a higher incidence in Japanese patients [4], and 
contribute to the pathogenesis of affected lung tumors. 
Targeted therapies have shown promise in the treatment 
of NSCLC, with studies selecting patients for molecular 
targets faring better in general [5-8]. Erlotinib, an EGFR 
inhibitor, is approved by the Federal Drug Administration 
(FDA) to treat locally advanced or metastatic NSCLC [9]. 
Most responses to erlotinib occur in patients with EGFR 
mutations [3, 10-12], and both resistant (e.g., L861Q) and 
sensitive (e.g., exon 18 G719S, exon 19 deletion or exon 
21 L858R point mutation) mutations have been identified 
[12-15]. Cetuximab, a monoclonal antibody to EGFR, has 
demonstrated efficacy in NSCLC when combined with 
chemotherapy [16], but is not currently FDA-approved 
for NSCLC.
Recently, Weihua, et al. [17] discovered that EGFR 
can maintain cancer cell survival independent of its 
kinase activity. This kinase-independent pathway operates 
via increased glucose uptake due to stabilization of the 
SGLT1 glucose transporter, with a downstream effect of 
reduced autophagy [17]. Therefore, targeting both kinase-
dependent and kinase-independent EGFR functions may 
be a rational treatment strategy. Indeed, studies in animal 
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models revealed that combining antibodies and kinase 
inhibitors was synergistic [18, 19]. Cetuximab blocks 
receptor activation by interfering with ligand binding, 
as well as down-regulating EGFR levels and inhibiting 
cell growth in association with inhibition of ligand-
independent EGFR signaling [20, 21]. Therefore, it is 
plausible that treatment with cetuximab could suppress 
kinase-independent cell signaling [21].
Angiogenesis also plays an important role in tumor 
development and metastasis [22], mediated in large part 
by vascular endothelial growth factor (VEGF) and its 
receptor VEGFR [23]. Bevacizumab is a recombinant anti-
VEGF monoclonal antibody FDA-approved for treatment 
of unresectable, locally-advanced, recurrent, or metastatic 
NSCLC in combination with paclitaxel and carboplatin [9, 
24].
Unfortunately, targeting angiogenesis or EGFR 
alone does not provide adequate tumor control in many 
patients [25-27]. Prior studies combining erlotinib and 
cetuximab or gefitinib and cetuximab failed to demonstrate 
tumor regressions in patients with lung adenocarcinomas 
resistant to erlotinib [28] or patients with NSCLC 
previously treated with platinum-based therapy [29], 
respectively. In contrast, targeting both VEGF and EGFR 
pathways demonstrated synergy in vivo [30, 31], possibly 
because resistance to EGFR inhibitors may be mediated 
at least partly by activating VEGF-dependent signaling 
as an alternative survival pathway [30, 31]. Furthermore, 
combining erlotinib and bevacizumab in patients with 
NSCLC who had not received prior anti-VEGF or anti-
EGFR treatment, showed response rates (CR/PR) of 18-
20% [31, 32] and improved progression-free survival 
(PFS), but not overall survival (OS) [33].
Here, we report, for the first time, the results of 
administering dual EGFR inhibitors (erlotinib plus 
cetuximab) together with an anti-angiogenic agent 




Thirty-four patients with NSCLC were enrolled 
(Table 2). All patients had progressive disease at the time 
of enrollment. Most patients were heavily pretreated, 
with a median of four prior therapies (range 1-8). Most 
patients (76%) had adenocarcinoma histology. Thirteen 
patients (38%) were previously treated with erlotinib, and 
11 patients (32%) had previously received bevacizumab.
Three of 19 patients tested (16%) had EGFR mutations; 
19 patients tested for KRAS mutations were all wild-type. 
The only patient tested for p53 had a mutation (R196*), 
and two patients out of nine tested had PIK3CA mutations 
(E542K and E545K). PTEN expression was tested by 
immunohistochemistry (n=3) or mutation analysis (n=2), 
and no aberrations were found.
Adverse Events
The most common treatment-related grade 
2 or higher adverse events were rash (n=14, 41%), 
hypomagnesemia (n=9, 26%), and fatigue (n=5, 15%) 
(Table 1). Treatment-related grade 2 hypotension, 
hemoptysis, neuropathy, vomiting, anorexia, infusion 
reaction, proteinuria, and grade 3 diarrhea were each 
observed in only one patient. Two patients experienced 
dose-limiting toxicity (DLT), including grade 3 rash (n=1, 
dose level 8) and grade 3 bronchospasm (n=1, dose level 
6). Twenty-four patients (71%) experienced no drug-
related toxicity higher than grade 1. Three patients (9%) 
withdrew due to toxicity, including grade 3 bronchospasm 
in cycle 1 (n=1), grade 1 diarrhea in cycle 1 (n=1), and 
grade 3 fatigue in cycle 4 (n=1). No deaths resulted from 
adverse events. The RP2D was level 8, which includes the 
recommended FDA-approved full dose of each medication 
[34].
responses
All 34 patients are included in the response data 
(Figure 1). Three patients withdrew before the first 
restaging assessment due to toxicity, and one patient 
withdrew early because of financial considerations. These 
four patients and any patients with clinical progression 
or new lesions are arbitrarily depicted as 21% increase 
(Figure 1) and are considered treatment failures. Four 
patients (12%) achieved a PR (two were unconfirmed PR 
(uPR)) and received treatment for 4, 6, 10, and 14 months 
(Table 3, Figure 2). Seven patients (21%) achieved stable 
disease (SD) lasting at least 6 months (duration was 6, 
6, 7, 9, 10, 12, and 25 months) (total SD≥6 months/PR/
uPR=11, (32%)).
Prior EGFr inhibitor or VEGF Inhibitor therapy 
and response
Of all 34 patients on study, seven patients (21%) 
had received prior erlotinib but no prior bevacizumab, 
five patients (15%) had received prior bevacizumab but 
no prior erlotinib, and six additional patients (18%) had 
received prior erlotinib and bevacizumab (five patients 
received prior sequential erlotinib and bevacizumab; 
one patient received prior concurrent erlotinib and 
bevacizumab). No patients had previously received 
cetuximab. Of seven patients who received prior erlotinib 
but no prior bevacizumab, two (29%) had SD≥6 months/
uPR. Of the five patients who received prior bevacizumab 
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but no prior erlotinib, three (60%) had SD≥6 months/uPR. 
Of the six patients who had received both prior erlotinib 
and bevacizumab, two (33%) achieved SD≥6 months/PR. 
The patient who received prior concurrent erlotinib and 
bevacizumab did not achieve SD≥6 months/PR.
Of the 11 patients with SD≥6 months/PR/uPR, 
four (36%) had prior EGFR inhibitor treatment (two with 
erlotinib alone and two with prior sequential erlotinib and 
bevacizumab), five (45%) had prior bevacizumab (three 
with bevacizumab alone and two with prior sequential 
erlotinib and bevacizumab), and four (36%) had neither 
prior erlotinib or bevacizumab  (Table 3). Prior EGFR 
and/or antiangiogenic treatment did not preclude SD≥6 
months/PR/uPR.
Among the four patients with SD≥6 months/PR/uPR 
who had received prior erlotinib, one patient had primary 
resistance to erlotinib alone, having developed progression 
after two months of erlotinib (Table 3, patient #146). 
Three patients (75%) received the combination treatment 
for as long or longer than the duration of the prior erlotinib 
(Table 3, patients #197, 90, and 146) (2, 5, and 13 months, 
respectively, with initial erlotinib treatment, and 6, 9, and 
14 months, respectively, with the combination treatment). 
Overcoming primary resistance to erlotinib and achieving 
a longer duration of treatment with this combination was 
demonstrated.
brain Metastases and response
Of 11 patients with brain metastases, three achieved 
a PR/uPR, and three had SD≥6 months (total six of 11, 
54%) (Table 3). One of these patients had five small, 
untreated brain metastases and achieved complete 
resolution of the brain tumors. The presence of brain 
metastases did not preclude SD≥6 months/PR/uPR.  
smoking History and response
Twenty-three (68%) of the patients had a history 
of smoking. Of these 23 patients, two (9%) achieved a 
PR/uPR, and five (22%) had stable disease SD≥6 months 
(total=31%), including one patient who was treated for 25 
months (Table 3). Of the 11 patients (32%) that did not 
have a history of smoking, two achieved a PR/uPR, and 
two had SD≥6 months (total=36%) (Table 3). Smoking 
history did not preclude SD≥6 months/PR/uPR.
Dosing and response
Of 17 patients on dose levels 7 or 8, six (35%) 
achieved SD≥6 months/PR/uPR. For patients treated at 
dose levels 1-6, five of 17 (29%) achieved SD≥6 months/
PR (Table 1 and Figure 1). The only patient treated on 


















Bevacizumab Dose, mg/kg IV q2w 2.5 5.0 5.0 5.0 7.5 7.5 7.5 10.0













Erlotinib Dose, mg PO daily 50 50 50 100 100 100 150 150
Fatigue
    Grade 2 0 0 0 0 0 2 0 2 4 (12%)
    Grade 3-4 0 0 0 0 0 0 0 1 1 (3%)
Rasha
    Grade 2 0 0 3 1 0 1 1 5 11 (32%)
    Grade 3-4 0 0 0 0 0 0 0 3 (DLT)b 3 (9%)
Hypomagnesemia
    Grade 2 0 1 0 1 0 0 0 1 3 (9%)
    Grade 3-4 0 0 0 1 0 1 0 4 6 (18%)
Nausea
    Grade 2 0 0 0 0 0 1 0 1 2 (6%)
    Grade 3-4 0 0 0 0 0 0 0 0
Abbreviations: DLT, dose-limiting toxicity; IV, intravenous; po, orally; q2w, every 2 weeks
†Recommended Phase II dose[33] (full approved doses of each drug).
*Cetuximab dose shown as loading dose, maintenance dose.
aIncluding pruritis
bOne out of the three events was considered a DLT.
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dose level 2 was stable for 6 months; two of the five 
patients treated on dose level 3 achieved SD≥6 months/
PR. There was no obvious dose-response correlation, 
although the number of patients was small.
Molecular Aberrations and responses
Of 16 patients with documented wild-type EGFR, 
five (31%) had SD≥6 months or uPR. Three of 19 patients 
tested for EGFR aberrations showed an abnormality, 
and one of the three patients, with an activating L858R 
mutation [35] and a G873E mutation, had a PR. This 
patient also demonstrated a co-existing PIK3CA 
mutation and had received prior sequential erlotinib 
and bevacizumab; on the current study, the patient has 
achieved a 55% regression and received treatment for 14 
months. The other two patients with EGFR aberrations 
(exon 20 insertion and exon 19 deletion) demonstrated 
20% and 11% regression, respectively, as best response, 
but the regressions were short—2 and 4 months on 
treatment, respectively. The presence of wild-type EGFR 
did not preclude achieving SD≥6 months/uPR. 
The only patient tested for p53 mutations had an 
R196* nonsense mutation. This patient achieved a 22% 
regression lasting 25 months.
Two of the nine total patients tested demonstrated 
PIK3CA mutations.  One had an E542K mutation (with 
concomitant EGFR mutation) and had a 55% regression, 
as mentioned above. The other patient, with an E545K 
mutation, had a 28% decrease (treatment duration=4 
months).  The presence of PIK3CA mutations did not 
preclude response.  
Three patients were tested for PTEN loss, and in all 
patients, PTEN expression was normal.  While PTEN loss 
can reflect a genetic aberration in NSCLC [36], the two 
patients tested for PTEN mutation were wild-type.
toxicity and response
Rash was the most frequently observed toxicity in 
patients (Table 1); 11 patients experienced grade 2 rash, of 
whom five (45%) achieved SD≥6 months/PR/uPR. Two of 
three patients with grade 3 rash or higher achieved SD≥6 
months/uPR (Table 3). Of 20 patients with grade 1 or no 
rash, four (20%) achieved SD≥6 months/PR/uPR. Patients 
with higher grade rash were significantly more likely to 
have SD≥6 months/PR/uPR (Spearman’s correlation 
coefficient, p<0.01). 
DIscUssION
In this study, we report the results of the cohort 
of patients with NSCLC treated on a phase I dose-
escalation trial of combination bevacizumab, cetuximab, 
and erlotinib. The rationale for this combination was: 
(1) preclinical and clinical studies that suggested 
increased activity when erlotinib was combined with 
bevacizumab [30, 31]; (2) preclinical studies indicating 
that EGFR signals through both kinase-dependent and 
-independent pathways [17]; and (3) studies demonstrating 
that combining an EGFR kinase inhibitor with EGFR 
antibodies was synergistic in animal models [18, 19].  
This combination of drugs was well-tolerated. The 
RP2D was determined to be the full FDA-approved doses 
for all three drugs [34], and 13 of the 14 patients (93%) 
treated at the RP2D tolerated treatment without drug-
related dose-limiting effects.
This regimen demonstrated antitumor activity in 
patients with NSCLC, including 11 patients (32%) who 
had a best overall response of SD≥6 months (n=7) or PR 
(n=4) (two PRs were unconfirmed). SD≥6 months/PR/uPR 
were observed even in patients who had received prior 
table 2:  Patient Demographics 
characteristics (n=34)
Age (years)
   Median 62
   Range 27-78
Gender, n (%)
   Men 18 (53%)
   Women 16 (47%)
Histologies, n (%) 
   Adenocarcinoma 26 (76%)
   Squamous cell 3 (9%)
   Mucinous adenocarcinoma 2 (6%)
   Poorly differentiated carcinoma 2 (6%)
   Sarcomatoid carcinoma 1 (3%)
No. of prior systemic therapies, n (%)
   Median 4
   Range 1-8
Prior bevacizumab, n (%) 11 (32%)
Prior EGFR inhibitors, n (%) 13 (38%)
EGFR mutations, n (%)
   Positive 3 (9%)
   Negative 16 (47%)
   Unknown 15 (44%)
KRAS mutations, n (%)
   Positive 0 (0%)
   Negative 19 (56%)
   Unknown 15 (44%)
History of smoking 23 (68%)
History of brain metastases 11 (32%)
ECOG performance status score, n (%)
   0 2 (6%)
   1 31 (91%)
   2 1 (3%)
Abbreviations: ECOG, Eastern Cooperative 
Oncology Group 
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bevacizumab and/or erlotinib, those with brain metastases, 
smokers, and patients treated at lower dose levels, so these 
characteristics do not preclude antitumor activity.
Remarkably, patients who previously had failed 
erlotinib also achieved SD≥6 months/PR/uPR. In fact, 
overcoming primary resistance to erlotinib and achieving 
a longer duration of treatment with this combination 
than with prior erlotinib alone was demonstrated. Recent 
preclinical studies suggest that combining EGFR kinase 
inhibitors and anti-EGFR antibodies may be more 
effective than either alone, perhaps because EGFR is able 
to maintain cancer cell survival independent of its kinase 
activity [17-19]. The clinical data presented here also 
support combining kinase inhibitors and antibodies.  
Previous phase I/II clinical studies combining 
cetuximab and erlotinib in patients with NSCLC failed 
to show significant tumor regression [28]. In contrast, 
as mentioned above, four patients on our study achieved 
a PR/uPR. The reason for this difference is unclear but 
could be due to the addition of bevacizumab in our 
regimen or because almost half of the patients treated on 
the prior study (but none in our study) had a known EGFR 
resistance mutation [37, 38]. It is important to use caution 
comparing the previous study to the results presented 
here because the previous study was conducted in a 
select group of patients, i.e., only patients with NSCLC 
who had received erlotinib throughout one month prior 
to enrollment and who had clinically-defined erlotinib 
resistance.
Prior studies combining erlotinib and bevacizumab 
showed PR/CR rates of 18-20% and improved PFS, but 
no improvement in OS, supporting a potential role for 
bevacizumab [32, 33]. However, these results cannot be 
compared directly with those in our study because patients 
in the prior studies were less heavily pretreated (median 
1-2 prior systemic regimens versus four in our study) and 
both prior studies excluded patients who had received 
previous EGFR or VEGF inhibitors.
The presence of brain metastases did not 
compromise the rate of SD≥6 months/PR/uPR. Five of 11 
patients with brain metastases achieved SD≥6 months/PR/
uPR, and one individual showed complete resolution of her 
brain metastases. No patient had intracranial hemorrhage. 
These results suggest that patients with NSCLC and brain 
metastases can safely receive this regimen and that it has 
activity, which is consistent with a previous studies on the 
Figure 1: best response in all 34 NscLc treated. Patients with early clinical progression, new lesions, or who withdrew early are 
indicated arbitrarily as +21% and denoted by †. Unconfirmed PRs are indicated by ♦. Patients who received prior bevacizumab are denoted 
by “B”, and patients who received prior erlotinib are denoted by “E”. No patients had cetuximab. Patients with wild-type EGFR are shown 
in green; patients with EGFR alterations are shown in red; and patients that were not tested for EGFR mutations are shown in blue. The 
specific mutation in EGFR, PIK3CA, and/or p53 is labeled for all patients that had mutations in one or more genes tested. The dose level 
and treatment duration (months) for each patient are shown in the table below.
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efficacy of TKIs against brain metastases in NSCLC [39].
SD≥6 months/PR/uPR were observed even at low 
dose levels. No dose-related difference was observed in 
the number of patients who achieved SD≥6 months/PR/
uPR (six of 17 patients at dose levels 7-8 versus five of 17 
patients at dose levels 1-6). These data are consistent with 
a previous study of 683 patients receiving treatment on 
phase I trials in our department which found that patients 
who received lower doses of predominantly targeted 
agents fared as well as those receiving higher doses [40].
Exploratory analysis of molecular aberrations 
was performed to identify potential subsets of patients 
with SD≥6 months/PR/uPR. EGFR, PIK3CA, PTEN, 
and p53 mutation data were available for 20 patients, 
including patients who had PTEN assessed by 
immunohistochemistry. Although the limited number 
of patients prevents definitive conclusions, it was noted 
that all five patients with molecular aberrations (EGFR 
mutations L848R and G873E and PIK3CA mutation 
E542K (n=1), EGFR exon 20 insertion (n=1), EGFR exon 
19 deletion (n=1), p53 mutation (n=1), PIK3CA mutation 
(n=1)) experienced tumor regression, which in some cases 
was prolonged.
Of special interest, out of 16 patients with 
documented wild-type EGFR, five (31%) achieved SD≥6 
months/uPR. Although EGFR mutations are generally 
found in lung cancer patients who are non-smokers [41], 
seven of 23 smokers (30%) achieved SD≥6 months/PR/
uPR. These data suggest that wild-type EGFR and/or a 
history of smoking did not preclude salutary effects with 
this regimen.
In regard to toxicity, previous studies have shown a 
correlation between rash and response to EGFR inhibitors 
[42]. In our study, patients who had higher grade rash were 
more likely to have SD≥6 months/PR/uPR (p<0.01). In 
previous studies of metastatic colorectal cancer combining 
bevacizumab, cetuximab, and cytotoxic chemotherapy, the 
addition of cetuximab shortened progression-free survival 
[43, 44]. In contrast, our trial combined bevacizumab and 
cetuximab without chemotherapy. Future studies should 
be pursued to further investigate this combination without 
chemotherapy.
Despite the promising responses observed in our 
study, most patients developed progressive disease, which 
Table 3: Characteristics for patients with any tumor regression or SD≥6 months (n=17)















37 Adenocarcinoma -59 10 Y ND ND ND N N Y 3 N
197 Mod. diff. adeno. -55 14 N L858RG873E E542K ND
Erlotinib
(13 months) Y Y 8 N
200 Poorly-mod. diff. adeno. -48♦ 4 Y NEG NEG ND N Y Y 8 Y






-24 10 N NEG NEG ND N N N 8 Y
39 SCC -22 25 Y NEG NEG R196* N N N 3 N
90 Mucinous adeno -16 9 N NEG NEG ND Erlotinib(5 months) N N 6 N
45 Adenocarcinoma -10 7 Y ND ND ND N Y Y 4 N
146 Adenocarcinoma 5 6 Y NEG NEG ND Erlotinib(2 months) Y Y 8 N
169 Adenocarcinoma 7 12 Y ND ND ND N Y Y 8 N
28 Adenocarcinoma 8 6 Y ND ND ND N N N 2 N
SD<6 Months and tumor decrease 0-29%
228 Adenocarcinoma -28 4 Y NEG E545K ND N N N 8 N
148 Adenocarcinoma -20 2 N Exon 20 insertion ND ND N Y N 8 Y
207 Adenocarcinoma -15 3 Y NEG NEG ND N N N 8 N
89 Poorly diff. adeno. -13 4 Y NEG ND ND N N N 6 N
181 Adenocarcinoma -11 4 Y Exon 19 deletion ND ND
Erlotinib
(12 months) Y N 8 N
40 Adenocarcinoma -5 2 Y ND ND ND N N Y 3 N
Abbreviations: adeno, adenocarcinoma; diff, differentiated; mod, moderately; ND, not done; NEG, negative; PR, partial response; SCC, 
squamous cell carcinoma; SD; stable disease; Tx, treatment
♦Indicates an unconfirmed PR.
Oncotarget 2013; 4: 118-127124www.impactjournals.com/oncotarget
may be explained by multiple potential mechanisms of 
resistance [45-47]. Future studies should be considered 
to further investigate causes of resistance in the clinical 
setting.
In conclusion, the results presented here demonstrate 
that dual inhibition of EGFR with erlotinib and cetuximab, 
combined with the VEGF antibody bevacizumab, is well-
tolerated, allowing full doses of all three drugs in patients 
with NSCLC. SD≥6 months/PR/uPR was achieved 
in 32% of this heavily pretreated patient population, 
including patients with brain metastases, smokers, 
those treated at lower doses, those with prior erlotinib 
and/or bevacizumab, and those with wild-type EGFR. 




The study was conducted at The University of 
Texas M. D. Anderson Cancer Center (MDACC) per 
Institutional Review Board guidelines. The lung cancer 
cohort reported herein included all patients with NSCLC 
who started therapy between 4/7/2008 and 12/27/2010 as 
part of a dose-escalation study conducted in patients with 
advanced cancer. The dose escalation portion of the study 
determined the recommended phase II dose (RP2D) to be 
bevacizumab 10 mg/kg IV every two weeks; cetuximab 
loading 400 mg/m2, maintenance 250 mg/m2 IV weekly; 
and erlotinib 150 mg PO daily [34]. A cycle was 28 days. 
Patients were treated at variable dose levels, depending on 
the time of study entry (Table 1).
Figure 2: computed tomography (ct) images of the three patients with the greatest tumor reduction. (A) patient #37 
(EGFR mutation not done, smoker), who achieved a PR (59% decrease), at baseline (i) and 32 weeks (ii), (B) patient #197 (EGFR L858R, 
G873E and PIK3CA E542K mutations, nonsmoker) who achieved a PR (55% decrease), at baseline (i) and 20 weeks (ii), and (C) patient 
#200 (EGFR wild-type, smoker), who achieved an unconfirmed PR (48% decrease), at baseline (i) and 8 weeks (ii). 
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Patients
Patients had metastatic or advanced NSCLC not 
amendable to standard therapy, an Eastern Cooperative 
Oncology Group (ECOG) performance status 0-2 [48], 
and adequate hematologic, hepatic, and renal function. 
Exclusion criteria included hemoptysis, unexplained 
bleeding, significant cardiovascular disease, intercurrent 
uncontrolled illness, significant gastrointestinal bleeding 
within 28 days, hemorrhagic brain metastases, prior 
abdominal surgery within 30 days, pregnancy, and a 
history of hypersensitivity to bevacizumab, cetuximab, 
and/or erlotinib. Treatment with prior cytotoxic therapies 
must have ended at least three weeks prior to enrollment, 
and biologic therapy must have ended at least two weeks 
or five drug half-lives prior to enrollment (whichever is 
shorter).
safety
Clinically significant adverse events were assessed 
according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE), 
version 3.0. History, physical exam, hematology, blood 
chemistry, and urinalysis were performed at baseline and 
regular intervals while receiving treatment.
Evaluation of Efficacy
Treatment efficacy was evaluated by diagnostic 
imaging per Response Evaluation Criteria in Solid 
Tumors (RECIST) 1.0 [49]. Radiologic assessments were 
conducted at baseline and about every 8 weeks thereafter.
Molecular testing
EGFR, KRAS, PIK3CA, p53, and PTEN 
mutation analysis, as well as PTEN expression by 
immunohistochemistry, were performed in the Clinical 
Laboratory Improvement Amendments (CLIA)-approved 
M.D. Anderson Cancer Center laboratory for patients with 
available archived tissue. For EGFR (exons 18-21 of the 
kinase domain), KRAS (codons 12, 13 and 61), PIK3CA 
(codons 532-554 in exon 9 and codons 1011-1062 in exon 
20), p53 (exons 4-9), and PTEN mutation (exons 1-9 
(entire coding sequence)) testing, PCR-based sequencing 
analysis was performed on DNA extracted from paraffin-
embedded tumor tissue. The lower limit of detection was 
approximately one cell bearing the mutation per five to 
ten normal cells. PTEN expression was determined by 
immunohistochemistry using anti-PTEN monoclonal 
mouse antibody (Dako, Carpinteria, CA).
statistical Analysis
No formal hypotheses were tested, and analyses 
were descriptive and exploratory.  Non-parametric 
correlations were determined with Spearman’s rank 
correlation coefficient.
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